Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Additional findings: Improvements in cholesterol levels and blood pressure were observed
Compare Noom's $3.7B valuation at its May 2021 Series F round to the legacy incumbent WeightWatchers (NASDAQ: WW) at $890M revenue in 2023 (down 15% YoY) with a $140M market cap (0.2x multiple), GLP-1 competitor Hims & Hers (NYSE: HIMS) at $872M revenue in 2023 (up 65% YoY) with a $3.95B market cap (4.5x multiple), and telehealth therapy company Talkspace (NASDAQ: TALK) at $150M revenue in 2023 (up 26% YoY) with a $431M market cap (2.8x multiple)
Semaglutide and tirzepatide are once-weekly injectable medications approved for chronic weight management, used in conjunction with lifestyle changes
Its administered weekly, making it relatively convenient for patients
